USPCM
SLNO

Union Square Park Capital Management’s Soleno Therapeutics SLNO Stock Holding History

Union Square Park Capital Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-20,000
Closed -$1.68M – 66
2025
Q2 		$1.68M Buy
+20,000
New +$1.5M 0.7% 38
2025
Q1 		– Sell
-50,000
Closed -$2.25M – 55
2024
Q4 		$2.25M Buy
+50,000
New +$2.59M 1.45% 24

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Union Square Park Capital Management's SLNO Position: Q3 2025 in Review

Union Square Park Capital Management sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 20,000 shares — an estimated $1.68M sold.

Union Square Park Capital Management first reported a position in SLNO in Q4 2024 and held it in 2 quarters. The position peaked at $2.25M in Q4 2024. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Union Square Park Capital Management reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Union Square Park Capital Management sold 20,000 Soleno Therapeutics shares in Q3 2025, an estimated $1.68M.
  • Union Square Park Capital Management first reported a position in Soleno Therapeutics in Q4 2024 and held it in 2 quarters.
  • Union Square Park Capital Management's Soleno Therapeutics position peaked at $2.25M in Q4 2024.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Union Square Park Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.